Post by
LongTerm3 on Feb 10, 2023 12:33pm
Thrivent Fund:
Thrivent has four different funds in Viemed stock totalling about 20% of the company, and has been buying during the year.
Company insiders have 17%.
There are 99 Institutions Holding Shares. The float has to be very low. For a few weeks volume went up and built a new base. The past week or so, volume was lower, but the share price is moving up. Earnings should be out within a month, and on all the calls this year they met there numbers.
Everything has opened up since Covid.
CMS rate increase in January. Patient count going up. I'm just telling facts, not trying to hype.
Comment by
JackLambert on Feb 10, 2023 2:22pm
Covid cost us three years growth. $10 per share. But - there is a bunch of over capacity in the company now. By design. Good people fully trained and positioned for success. Marketwatch says each headcount drives $125k of revenue. I'm guessing we have capacity for up to $ 20 million new revenue without adding new staff.
Comment by
LongTerm3 on Feb 10, 2023 3:06pm
Do to Covid, they sold lots of extra equipment. Viemed was able to build up a huge cash position to buy more equipment, and two buildings for cash. So it did do some good. I think there are fewer shares outstanding from two years ago, with the two by backs. So it wasn't so bad.
Comment by
JackLambert on Feb 10, 2023 3:58pm
You're right too. We call that canny management.